摘要
垂体癌(pituitary carcinoma)是一种较为罕见的侵袭性恶性肿瘤,可浸润邻近组织,包括海绵窦、骨、蝶窦等,且常规治疗无效。在没有恶性肿瘤组织学特征的情况下,只有出现脑、脊髓或全身转移时,才能证实垂体癌的存在。其生长快速、频繁复发、诊断延迟滞后、常规治疗效果不佳以及预后差等特点,使垂体癌的综合管理与治疗十分困难。本文通过对垂体癌诊治的最新研究进展进行综述,加强临床医生对该病的认识,尽可能提高患者的长期生存率。
Pituitary carcinoma(PC)is a rare invasive malignant tumor,which can invade adjacent tissues,including cavernous sinus,bone,sphenoid sinus,etc.,and it is ineffective to conventional treatment.Without histological features of malignant tumors,PC could be confirmed only when cerebrospinal or systemic metastases were present.Moreover,the characteristics of rapid growth,frequent recurrence,delayed diagnosis,poor response to conventional treatment,and poor prognosis make it difficult to manage and treat synthetically.This article reviewed the latest progress in the diagnosis and treatment of pituitary carcinoma,so as to strengthen the clinicians′knowledge of the disease and improve the long-term survival rate of patients as much as possible.
作者
董文静
颜世举
赵健
谷伟军
Dong Wenjing;Yan Shiju;Zhao Jian;Gu Weijun(Chinese PLA Medical College,Beijing 100039,China;Department of Gerontology,Hainan Hospital of Chinese PLA General Hospital,Sanya 572013,China;Department of Endocrinology,the First Medical Center of Chinese PLA General Hospital,Beijing 100853,China)
出处
《国际内分泌代谢杂志》
2024年第4期246-249,278,共5页
International Journal of Endocrinology and Metabolism
基金
北京市自然科学基金面上基金项目(7232155)。
关键词
垂体癌
替莫唑胺
靶向治疗
肽受体放射性核素治疗
Pituitary carcinoma
Temozolomide
Targeted therapy
Peptide receptor radionuclide therapy